Jounce, F-star, and Astria Therapeutics
End-of-year summary and predictions into 2023
Ending a rather difficult 2022 with a few quick notes on names that were written about this year.
Jounce’s $67M Asset Sale
Gilead acquired the remaining rights to the anti-CCR8 antibody that was in co-development with Jounce Therapeutics (JNCE). Jounce received $67M and, as a result, will no longer be entitled to receive the remaining contingent payments …